# Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma

> **NCT03123276** · PHASE1,PHASE2 · COMPLETED · sponsor: **Royal Marsden NHS Foundation Trust** · enrollment: 25 (actual)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT03123276
- **Lead sponsor:** Royal Marsden NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-29
- **Primary completion:** 2022-05-20
- **Final completion:** 2022-05-20
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2026-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03123276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03123276, "Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma". Retrieved via AI Analytics 2026-05-20 from https://api.ai-analytics.org/clinical/NCT03123276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*